Boston Scientific has a couple of more weeks if needed to complete due diligence. |
Boston's overall sales growth is going to slip to 5 percent in the second half of this year and go flat in 2006. The new-product portfolio Boston is piecing together can restore double-digit earnings and sales growth, but it will probably take until 2009. |
Even with the new components of the Boston offer, we don't think Guidant's board will get comfortable enough with the aforementioned antitrust issues and the extra $1. |
It seems like (Johnson & Johnson and Boston Scientific) are going to dominate the market at least through '06. |
That cash is going somewhere. It ain't going to buy back shares. |
The odds of them stopping this are not high. They are fully committed to walking. |
They are destroying the value of their company for a damaged asset. What is their board thinking? |
They walked away, and they got $700 million for their trouble. I don't really see a problem here. |